PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial

(2021) Samer Gawrieh et al.   HEPATOLOGY

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

(2021) Atsushi Nakajima et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target

(2021) Vittoria Infantino et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

ACLY Nuclear Translocation in Human Macrophages Drives Proinflammatory Gene Expression by NF-κB Acetylation

(2021) Anna Santarsiero et al.   Cells

Mitochondria-Mediated Apoptosis of HCC Cells Triggered by Knockdown of Glutamate Dehydrogenase 1: Perspective for Its Inhibition through Quercetin and Permethylated Anigopreissin A

(2021) Michela Marsico et al.   Biomedicines

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content

(2020) Yusuke Sasaki et al.   Scientific Reports

Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study

(2020) Yuya Seko et al.   HEPATOLOGY RESEARCH

Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications

(2019) Agha Zeeshan Mirza et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

(2019) Upendra Kaul et al.   Cardiovascular Diabetology

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

(2019) Jean-Charles Fruchart et al.   Cardiovascular Diabetology

TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma

(2019) Simona Todisco et al.   Cancers

Molecular actions of PPARα in lipid metabolism and inflammation

(2018) Nadia Bougarne et al.   ENDOCRINE REVIEWS

Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease

(2018) Mario Masarone et al.   Oxidative Medicine and Cellular Longevity

Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma

(2018) Vittoria Infantino et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

(2017) Yong-ho Lee et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Endogenous catalase delays high-fat diet-induced liver injury in mice

(2017) Lingjuan Piao et al.   KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY

Nuclear receptors and nonalcoholic fatty liver disease 1 1This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr. Wen Xie.

(2016) Matthew C. Cave et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Hepatic dysfunction in peroxisomal disorders

(2016) Myriam Baes et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Interfaces between mitochondrial dynamics and disease

(2016) Prashant Mishra   CELL CALCIUM

Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice

(2016) Camella G. Wilson et al.   ENDOCRINOLOGY

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD

(2016) Alexandra Montagner et al.   GUT

The contribution of the citrate pathway to oxidative stress in Down syndrome

(2016) Paolo Convertini et al.   IMMUNOLOGY

ROS and ROS-Mediated Cellular Signaling

(2016) Jixiang Zhang et al.   Oxidative Medicine and Cellular Longevity

Statins Increase Mitochondrial and Peroxisomal Fatty Acid Oxidation in the Liver and Prevent Non-Alcoholic Steatohepatitis in Mice

(2016) Han-Sol Park et al.   Diabetes & Metabolism Journal

Mitochondrial ROS metabolism: 10 Years later

(2015) A. Y. Andreyev et al.   BIOCHEMISTRY-MOSCOW

The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes

(2015) Maria Thomas et al.   BMC CANCER

On the Metabolically Active Form of Metaglidasen: Improved Synthesis and Investigation of Its Peculiar Activity on Peroxisome Proliferator-Activated Receptors and Skeletal Muscles

(2015) Antonio Laghezza et al.   ChemMedChem

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

(2015) Sven Francque et al.   JOURNAL OF HEPATOLOGY

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

(2015) Michal Pawlak et al.   JOURNAL OF HEPATOLOGY

Recent insights into the biological functions of liver fatty acid binding protein 1

(2015) GuQi Wang et al.   JOURNAL OF LIPID RESEARCH

Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions

(2015) Wang-Soo Lee et al.   PPAR Research

H2O2 release from the very long chain acyl-CoA dehydrogenase

(2015) Pâmela A.H.B. Kakimoto et al.   Redox Biology

Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease

(2014) Un Jung et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Hepatic ATGL mediates PPAR-α signaling and fatty acid channeling through an L-FABP independent mechanism

(2014) Kuok Teong Ong et al.   JOURNAL OF LIPID RESEARCH

Integrated physiology and systems biology of PPARα

(2014) Sander Kersten   Molecular Metabolism

Transcriptional Control by NF-κB: Elongation in Focus

(2013) Gil Diamant et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Pathophysiology of NASH: Perspectives for a Targeted Treatment

(2013) Fabio Marra et al.   CURRENT PHARMACEUTICAL DESIGN

Activation of PPAR  Ameliorates Hepatic Insulin Resistance and Steatosis in High Fructose-Fed Mice Despite Increased Endoplasmic Reticulum Stress

(2013) S. M. H. Chan et al.   DIABETES

Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

(2013) B. Cariou et al.   DIABETES CARE

PPARα agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway

(2013) Weirong Wang et al.   EXPERIMENTAL CELL RESEARCH

Involvement of free radicals and oxidative stress in NAFLD/NASH

(2013) Y. Sumida et al.   FREE RADICAL RESEARCH

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

The Protective Effect of Fenofibrate Against TNF-α-Induced CD40 Expression through SIRT1-Mediated Deacetylation of NF-κB in Endothelial Cells

(2013) Weirong Wang et al.   INFLAMMATION

Genetics and molecular basis of human peroxisome biogenesis disorders

(2012) Hans R. Waterham et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Mitochondria: In Sickness and in Health

(2012) Jodi Nunnari et al.   CELL

Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPARα) in human hepatocarcinoma HepG2 cells by activation of NF-κB pathway

(2012) Wyi Sian Lim et al.   CYTOKINE

Suppression of Oxidative Stress by  -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor

(2012) T. Shimazu et al.   SCIENCE

Mechanisms of Gene Regulation by Fatty Acids

(2012) Anastasia Georgiadi et al.   Advances in Nutrition

Hepatosteatosis in peroxisome deficient liver despite increased β-oxidation capacity and impaired lipogenesis

(2011) Annelies Peeters et al.   BIOCHIMIE

Human SREBP1c Expression in Liver Is Directly Regulated by Peroxisome Proliferator-activated Receptor α (PPARα)

(2011) Ana Fernández-Alvarez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Control of Macrophage Activation and Function by PPARs

(2010) Ajay Chawla   CIRCULATION RESEARCH

Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c

(2010) P. Ferré et al.   DIABETES OBESITY & METABOLISM

WY-14 643, a Selective PPARα Agonist, Induces Proinflammatory and Proangiogenic Responses in Human Ocular Cells

(2010) Jin-Zhong Zhang et al.   INTERNATIONAL JOURNAL OF TOXICOLOGY

Peroxisomal and Microsomal Lipid Pathways Associated with Resistance to Hepatic Steatosis and Reduced Pro-inflammatory State

(2010) Diana Hall et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

(2010) Elisa Fabbrini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism

(2010) Paul P. Van Veldhoven   JOURNAL OF LIPID RESEARCH

Liver fatty acid-binding protein and obesity

(2010) Barbara P. Atshaves et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression

(2009) Vito Iacobazzi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Reactive oxygen species and peroxisomes: Struggling for balance

(2009) Nina A. Bonekamp et al.   BIOFACTORS

Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice

(2009) Maaike H. Oosterveer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myopathy with statin–fibrate combination therapy: clinical considerations

(2009) Terry A. Jacobson   Nature Reviews Endocrinology

Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human

(2009) Maryam Rakhshandehroo et al.   PLoS One

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

(2008) C. Fernández-Miranda et al.   DIGESTIVE AND LIVER DISEASE

Metabolic profiling of PPARα−/− mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation

(2008) Liza Makowski et al.   FASEB JOURNAL

PPAR.ALPHA. and PPAR.DELTA. Transactivity and p300 Binding Activity Induced by Arachidonic Acid in Colorectal Cancer Cell Line Caco-2

(2008) Kazuki MOCHIZUKI et al.   JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY

Effect of Synthetic Dietary Triglycerides: A Novel Research Paradigm for Nutrigenomics

(2008) Linda M. Sanderson et al.   PLoS One

Fibrates and future PPARα agonists in the treatment of cardiovascular disease

(2008) Bart Staels et al.   Nature clinical practice. Cardiovascular medicine